Five-year study GAP for prevention of asthma in children suffering from grass pollen allergy using sublingual immunotherapy with Grazax

Abstract

Allergen immunotherapy is targeted at the immunological basis of allergic rhinoconjunctivitis and allergic asthma and it has the potential to modify the natural course of the allergic disease. GAP study (Grazax Asthma Prevention) aimed to evaluate whether sublingual immunotherapy influences the risk of asthma development in childhood in comparison with placebo.

Keywords

• children
• allergen immunotherapy
• allergic rhinoconjunctivitis
• allergic asthma
• long-term study
• GAP (Grazax Asthma Prevention)